Work

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps7593

Authors: Neha Mehta-Shah, Susan Michelle Geyer, Stefan K. Barta, Jennifer Effie Amengual, Travis Dockter, Chadwick Wright, Shira Dinner, Eric D. Hsi, Nancy L. Bartlett, Steven M. Horwitz, Brad S. Kahl, Jonathan W. Friedberg, John Paul Leonard

Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University, University of Pennsylvania, Columbia University Irving Medical Center, The Ohio State University Wexner Medical Center, Northwestern Memorial Hospital, Wake Forest University Health Sciences, Wake Forest University, Washington University in St. Louis, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Rochester Medicine, NewYork–Presbyterian Hospital, Weill Cornell Medicine

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281946236

Cites:

Cited by: 5

Related to: 10